Icon PlcICLR

ICON PLC is the contract research organisation that signs the cheques while subcontracting the actual drug trials to investigators whose fees are set by OECD transfer-pricing guidelines rather than Hollywood agents. The company’s 20-F for the year ended 31 December 2025 shows revenue of $8.25 billion, net income attributable to the parent of $229.3 million, diluted EPS of $2.90 on 79.0 million diluted shares, and $647.3 million of cash at its disposal.

The ‘Accelerated Early Clinical Manufacturing services’ line on ICON’s product page is best visualised as a high-throughput production kitchen churning out investigational medicinal product in full current good manufacturing practice compliance. ICON describes itself as the contract principal for both direct services and the use of third-party investigator networks that support clinical research projects, while its Irish subsidiary is remunerated on an arm’s-length return basis aligned with the 2022 OECD transfer-pricing guidelines.

Operating income for 2025 was $442.8 million against liabilities of $7.08 billion and total assets of $16.27 billion, producing shareholders’ equity of $9.19 billion. Cash generated from operations was $1.04 billion, capex was $174.2 million, and the board has scheduled an earnings call on 99.1 for the second quarter of 2026 to discuss the next tranche of contract income.

ICON’s official manufacturing and pharmacy services page confirms the company’s full range of clinical, consulting and commercial services across several industry sectors, but the filings do not quantify segment-level profitability or customer concentration beyond the global revenue figure. The evidence therefore establishes the shape and scale of ICON’s outsourced-services model without revealing how much profit accrues to any single therapeutic area or customer relationship.

The 20-F and 6-K filings are the primary sources; SEC EDGAR URLs are provided for each document. There is no evidence in the supplied rail that quantifies pipeline value, customer concentration, or specific clinical-trial wins beyond the plain revenue disclosure, so the source requires readers to treat segment depth and customer concentration as unproven.